NEXSTAR DAUNOXOME RECOMMENDATION FOR FIRST-LINE USE IN ADVANCED KAPOSI's SARCOMA BOOSTED BY RANDOMIZED TRIAL; EFFICACY AND TOXICITY COMPARABLE TO ABV
NeXstar's randomized trials for its liposomal daunorubicin DaunoXome in advanced AIDS-related Kaposi's sarcoma may set a precedent for AIDS therapies to follow. Based on the results of the studies, eight members of FDA's Oncologic Drugs Advisory Committee voted June 8 to recommend DaunoXome as a first-line therapy for advanced KS.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth